{"filing":{"accession_number":"0001193125-26-385331","cik":"0001658551","ticker":"AMLX","company_name":"Amylyx Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-01","primary_document":"d160615d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526385331/d160615d8k.htm"},"events":[{"id":32063,"run_id":29453,"accession_number":"0001193125-26-385331","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Amylyx entered into manufacturing and supply agreements with Bachem (definitive) and Polypeptide (term sheet) to secure long-term supply of avexitide drug substance for commercial use. While Item 1.01 typically covers M\u0026A activity, these are strategic operational/supply agreements essential to the company's ability to commercialize its lead drug candidate, not acquisitions or dispositions. The agreements establish minimum purchase commitments beginning in 2028 and include a $30 million upfront fee to Polypeptide, making this a material operational milestone for a biopharmaceutical company dependent on third-party manufacturing.","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35137,"accession_number":"0001193125-26-385331","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Amylyx entered into manufacturing and supply agreements with Bachem (definitive) and Polypeptide (term sheet) to secure long-term supply of avexitide drug substance for commercial use. While Item 1.01 typically covers M\u0026A activity, these are strategic operational/supply agreements essential to the company's ability to commercialize its lead drug candidate, not acquisitions or dispositions. The agreements establish minimum purchase commitments beginning in 2028 and include a $30 million upfront fee to Polypeptide, making this a material operational milestone for a biopharmaceutical company dependent on third-party manufacturing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:55:58.488227+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35137,"accession_number":"0001193125-26-385331","item_number":"1.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Amylyx entered into manufacturing and supply agreements with Bachem (definitive) and Polypeptide (term sheet) to secure long-term supply of avexitide drug substance for commercial use. While Item 1.01 typically covers M\u0026A activity, these are strategic operational/supply agreements essential to the company's ability to commercialize its lead drug candidate, not acquisitions or dispositions. The agreements establish minimum purchase commitments beginning in 2028 and include a $30 million upfront fee to Polypeptide, making this a material operational milestone for a biopharmaceutical company dependent on third-party manufacturing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:55:58.488227+00:00","company_name":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","filing_date":"2026-09-08"}]}